Bispecific DIscovery
Accelerating bispecific antibody discovery for next-generation therapies
Advance your project from concept to optimized therapeutic lead with Alloy’s comprehensive bispecific discovery services.
Bring your bispecific programs to life with Alloy’s end-to-end discovery and engineering capabilities
Partner with a knowledgeable team that delivers rank-ordered bispecific candidates tailored to your target. Our comprehensive approach integrates various technologies and custom, proprietary workflows that ensure precise, high quality bispecific leads.
CLC & VHH Discovery Solutions
Format Engineering & Optimization
High-throughput Screening
Rank-ordered bispecific candidates that match your target affinity, cross-reactivity, specificity, and functional activity.
Modular antibody domains
Discover high-quality monoclonal antibodies in our suite of ATX mice, including the ATX-CLC strain for common light chain antibodies that can be combined into highly manufacturable bispecifics.
Flexible bispecific production
Efficiently build large bispecific panels in a range of formats to explore the impact of monoclonal combinations, valency, and orientation.
Integrated functional testing
Rapidly screen your bispecific panels in high-throughput biophysical and functional assays including cell killing, cytokine release, internalization, and more.
Off-the-shelf binding arms
Streamline your bispecific project by integrating off-the-shelf binding arms for high value targets including tumor antigens, T-cell engagers, and delivery shuttles.
Offering Details
Next-gen bispecific discovery with unmatched flexibility, precision, and speed
We’ve developed advanced workflows for bispecific engineering and screening that integrate format optimization, high-throughput expression, biophysical characterization, and disease specific functional screening.
Modular antibody discovery platforms for streamlined bispecific production
Two platforms provide a foundation of modular building blocks that can be combined in a range of highly developable bispecific formats.
Learn more
ATX-CLC MOUSE
Our ATX-CLC common light chain mouse platform produces panels of high-quality, diverse antibodies that share a single light chain sequence. These domains can be combined in a range of multispecific formats while maintaining their native fragment antigen-binding (Fab) architecture, producing bispecifics with the drug-like properties of monoclonals.
IN VITRO VHH
Our in vitro VHH platforms for discovery of fully human, single domain antibodies with robust developability can be further combined with antibody domains to form diverse multispecifics.
Flexible, fit-for-purpose formats engineered by a team of experts
Starting with our modular monoclonal building blocks including CLC & VHH domains, we leverage our high-throughput expression capabilities to build out diverse panels of bispecifics combining different monoclonal pairs. Based on our partner’s target product profile, our experienced teams will further incorporate different orientations, valencies, and Fc modifications where appropriate.
All bispecifics undergo rigorous QC for purity and drug-like properties prior to functional testing to ensure that your functional hits translate to developable drugs.
Integrated functional testing to rapidly identify your therapeutic lead
At Alloy, we integrate functional testing into our antibody discovery and bispecific engineering workflows to streamline hit selection and reduce your program timelines. We work with our partners to develop a customized assay cascade that delivers an optimized bispecific for therapeutic development.
Streamline hit Selection with:
- Antibody-dependent cellular cytotxocity
- T cell killing
- Cytokine release assay
- Antibody-dependent cellular phagocytosis
- Reporter cell lines
- Cellular internalization
Off-the-shelf binding arms to accelerate your bispecific program
Alloy offers a variety of well-characterized binding arms against high-value antigens including CD3 and CD28 for T cell engagers, TfR1 for delivery, and other targets across oncology and immunology that can be incorporated into your bispecific program to accelerate and de-risk development. Most are built on our CLC or VHH technologies making them highly modular for combining with novel targeting arms.
target classes
- Cell engagers
- Immune modulators
- Delivery
- Tumor targets
Start your next bispecific discovery campaign with us
Launch your bispecific discovery with a customized approach to discovery that generates bispecifics you can bring to the clinic.
Explore our additional capabilities and services for your therapeutic success
Learn more about our full suite of services and offerings designed to accelerate your path from target to clinic.
